Cargando…

Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients

OBJECTIVE: NF1 is a tumor suppressor gene that encodes the neurofibromin protein and negatively regulates Ras signaling. This study was aimed to investigate the molecular, clinical characteristics, and prognostic features of NF1 gene in EGFR mutant lung cancer patients. METHOD: The next‐generation s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Hong‐xia, Chen, Zhi‐hong, Jie, Guang‐Ling, Wang, Zhen, Yan, Hong‐hong, Wu, Si‐pei, Zhang, Shui‐lian, Lu, Dan‐xia, Zhang, Xu‐chao, Wu, Yi‐long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844590/ https://www.ncbi.nlm.nih.gov/pubmed/35702826 http://dx.doi.org/10.1002/cam4.4925

Ejemplares similares

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism
por: Liu, Si‐Yang, et al.
Publicado: (2020)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
por: Wei, Xue-Wu, et al.
Publicado: (2022)

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
por: Zheng, Hongmei, et al.
Publicado: (2019)

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial
por: Zhou, Qing, et al.
Publicado: (2016)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023)

Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer
por: Yin, Zi-Jun, et al.
Publicado: (2018)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

Neuro–Magnetic Resonance Imaging in Hand, Foot, and Mouth Disease: Finding in 412 Patients and Prognostic Features
por: Lian, Zhou-yang, et al.
Publicado: (2017)

Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
por: Cheng, Hua, et al.
Publicado: (2011)

The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs
por: Zhang, Yuan, et al.
Publicado: (2018)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
por: Liu, Si-Yang Maggie, et al.
Publicado: (2023)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
por: Xia, Leiming, et al.
Publicado: (2021)

Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours
por: Yue-Yun, Chen, et al.
Publicado: (2019)

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma
por: Yang, Lei, et al.
Publicado: (2022)

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
por: Wang, Aoli, et al.
Publicado: (2016)

Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis
por: Hong, Xiaohua, et al.
Publicado: (2022)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
por: Hu, Chen, et al.
Publicado: (2017)

Clinicopathological features of patients with transformation from EGFR mutant lung adenocarcinoma to small cell lung cancer
por: Bai, Wenwen, et al.
Publicado: (2021)

Resistance mechanisms and fitness of Salmonella Typhimurium and Salmonella Enteritidis mutants evolved under selection with ciprofloxacin in vitro
por: Zhang, Chuan-Zhen, et al.
Publicado: (2017)

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
por: Zhou, Qing, et al.
Publicado: (2022)

Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis
por: Lv, Fangfang, et al.
Publicado: (2021)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
por: Li, Ling, et al.
Publicado: (2020)

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
por: Gou, Lan-Ying, et al.
Publicado: (2016)

The prognostic role of nutrition risk score (NRS) in patients with metastatic or recurrent esophageal squamous cell carcinoma (ESCC)
por: Zhou, Xia, et al.
Publicado: (2017)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer
por: Gao, Xin, et al.
Publicado: (2020)

FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in EGFR-Mutant NSCLC Cells
por: Feng, Jingwen, et al.
Publicado: (2022)

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
por: Galvani, Elena, et al.
Publicado: (2015)

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
por: Hu, Di, et al.
Publicado: (2023)

Low Prognostic Nutritional Index Correlates with Worse Survival in Patients with Advanced NSCLC following EGFR-TKIs
por: Sheng, Jin, et al.
Publicado: (2016)

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
por: Wang, Xiaoyuan, et al.
Publicado: (2018)

Identification of Six Prognostic Genes in EGFR–Mutant Lung Adenocarcinoma Using Structure Network Algorithms
por: Zhang, Haomin, et al.
Publicado: (2021)

Comprehensive Analysis and Experimental Validation of a Novel Estrogen/Progesterone-Related Prognostic Signature for Endometrial Cancer
por: Yu, Jing, et al.
Publicado: (2022)

EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
por: Hong, Sook-hee, et al.
Publicado: (2022)

Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer
por: Kim, Tae-Jung, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rmavd6gkogikd5tqq0sqij7q0f